PE20171738A1 - Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos - Google Patents
Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismosInfo
- Publication number
- PE20171738A1 PE20171738A1 PE2017001969A PE2017001969A PE20171738A1 PE 20171738 A1 PE20171738 A1 PE 20171738A1 PE 2017001969 A PE2017001969 A PE 2017001969A PE 2017001969 A PE2017001969 A PE 2017001969A PE 20171738 A1 PE20171738 A1 PE 20171738A1
- Authority
- PE
- Peru
- Prior art keywords
- formula compound
- compound
- preparation
- androgen receptor
- intermediaries
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
SE REFIERE A UN PROCESO PARA LA PREPARACION DE UN ANTAGONISTA DEL RECEPTOR ANDROGENO (AR) QUE ES EL COMPUESTO N-((S)-1-(3-(3-CLORO-4-CIANOFENIL)-1H-PIRAZOL-1-IL)-PROPAN-2-IL)-5-(1-HIDROXIETIL)-1H-PIRAZOL-3-CARBOXAMIDA (1A) QUE COMPRENDE LAS SIGUIENTES ETAPAS: i) HACER REACCIONAR EL COMPUESTO DE FORMULA (V) CON EL COMPUESTO DE FORMULA (VI) PARA PRODUCIR EL COMPUESTO DE FORMULA (VII); ii) HACER REACCIONAR EL COMPUESTO DE FORMULA (VII) CON EL COMPUESTO DE FORMULA (VIII) PARA PRODUCIR EL COMPUESTO DE FORMULA (IX); Y iii) REDUCIR EL COMPUESTO DE FORMULA (IX) PARA OBTENER EL COMPUESTO DE FORMULA (1A). DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DE CANCER DE PROSTATA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20150111 | 2015-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20171738A1 true PE20171738A1 (es) | 2017-12-04 |
Family
ID=55802393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017001969A PE20171738A1 (es) | 2015-04-09 | 2016-04-08 | Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos |
Country Status (30)
Country | Link |
---|---|
US (1) | US10189789B2 (es) |
EP (1) | EP3280710B1 (es) |
JP (1) | JP6707560B2 (es) |
KR (1) | KR102628078B1 (es) |
CN (1) | CN107428695B (es) |
AU (1) | AU2016245278B2 (es) |
BR (1) | BR112017021636B1 (es) |
CA (1) | CA2980965C (es) |
CL (2) | CL2017002491A1 (es) |
CO (1) | CO2017010052A2 (es) |
CY (1) | CY1123105T1 (es) |
DK (1) | DK3280710T3 (es) |
ES (1) | ES2800828T3 (es) |
HK (1) | HK1250710A1 (es) |
HR (1) | HRP20200707T1 (es) |
HU (1) | HUE049144T2 (es) |
IL (1) | IL254629B (es) |
LT (1) | LT3280710T (es) |
MX (1) | MX2017012910A (es) |
MY (1) | MY185488A (es) |
PE (1) | PE20171738A1 (es) |
PL (1) | PL3280710T3 (es) |
PT (1) | PT3280710T (es) |
RS (1) | RS60184B1 (es) |
RU (1) | RU2719590C2 (es) |
SG (1) | SG11201707959VA (es) |
SI (1) | SI3280710T1 (es) |
UA (1) | UA120777C2 (es) |
WO (1) | WO2016162604A1 (es) |
ZA (1) | ZA201706671B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021506962A (ja) * | 2017-12-19 | 2021-02-22 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーBoehringer Ingelheim Vetmedica GmbH | 1−シアノ−2−(4−シクロプロピル−ベンジル)−4−(β−D−グルコピラノス−1−イル)−ベンゼン、L−プロリンおよび水からなる1:1:1共結晶の合成 |
US11236070B2 (en) | 2019-05-16 | 2022-02-01 | Novartis Ag | Chemical process |
JP2022539142A (ja) | 2019-07-02 | 2022-09-07 | オリオン コーポレーション | ダロルタミドの医薬組成物 |
CN110590668A (zh) * | 2019-07-17 | 2019-12-20 | 江苏君若医药有限公司 | N-[(1s)-2-[3-(3-氯-4-氰基苯基)-1h-吡唑-1-基]-1-甲基乙基]-5-(1-羟基乙基)- 1h-吡唑-3-甲酰胺的制备方法 |
CN110483534B (zh) * | 2019-07-23 | 2021-05-18 | 上海药明康德新药开发有限公司 | 一种(2,4,5,7-四氢吡喃并[3,4-c]吡唑-7-基)甲醇的制备方法 |
CN111116476A (zh) * | 2019-12-27 | 2020-05-08 | 武汉九州钰民医药科技有限公司 | 制备抗肿瘤药物多拉米胺的方法 |
CN111116477B (zh) * | 2019-12-27 | 2021-04-20 | 武汉九州钰民医药科技有限公司 | 多拉米胺的合成工艺 |
MX2022014102A (es) | 2020-05-11 | 2022-12-08 | Orion Corp | Metodo para la preparacion de antagonistas de los receptores de androgenos e intermediarios de los mismos. |
CN113527208A (zh) * | 2021-08-31 | 2021-10-22 | 江西金丰药业有限公司 | 一步法制备2-氯-4-(1h-吡唑-3-基)苯甲腈的方法 |
CN113861115A (zh) * | 2021-09-10 | 2021-12-31 | 浙江师范大学 | 一种吡唑酰胺类衍生物及合成方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR078793A1 (es) * | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
BR112013026905B1 (pt) * | 2011-04-21 | 2021-09-14 | Orion Corporation | Compostos de carboxamida moduladora do receptor de andrógeno e seu uso no tratamento e prevenção de câncer de próstata, bem como composições farmacêuticas compreendendo os ditos compostos |
MX343688B (es) * | 2011-05-06 | 2016-11-16 | Zafgen Inc | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. |
-
2016
- 2016-04-08 PT PT167176726T patent/PT3280710T/pt unknown
- 2016-04-08 EP EP16717672.6A patent/EP3280710B1/en active Active
- 2016-04-08 RU RU2017134662A patent/RU2719590C2/ru not_active Application Discontinuation
- 2016-04-08 MX MX2017012910A patent/MX2017012910A/es unknown
- 2016-04-08 ES ES16717672T patent/ES2800828T3/es active Active
- 2016-04-08 PL PL16717672T patent/PL3280710T3/pl unknown
- 2016-04-08 RS RS20200496A patent/RS60184B1/sr unknown
- 2016-04-08 BR BR112017021636-1A patent/BR112017021636B1/pt active IP Right Grant
- 2016-04-08 WO PCT/FI2016/050220 patent/WO2016162604A1/en active Application Filing
- 2016-04-08 US US15/564,878 patent/US10189789B2/en active Active
- 2016-04-08 PE PE2017001969A patent/PE20171738A1/es unknown
- 2016-04-08 CN CN201680018881.7A patent/CN107428695B/zh active Active
- 2016-04-08 HU HUE16717672A patent/HUE049144T2/hu unknown
- 2016-04-08 MY MYPI2017703709A patent/MY185488A/en unknown
- 2016-04-08 KR KR1020177032529A patent/KR102628078B1/ko active IP Right Grant
- 2016-04-08 JP JP2017552929A patent/JP6707560B2/ja active Active
- 2016-04-08 DK DK16717672.6T patent/DK3280710T3/da active
- 2016-04-08 SG SG11201707959VA patent/SG11201707959VA/en unknown
- 2016-04-08 SI SI201630674T patent/SI3280710T1/sl unknown
- 2016-04-08 CA CA2980965A patent/CA2980965C/en active Active
- 2016-04-08 AU AU2016245278A patent/AU2016245278B2/en active Active
- 2016-04-08 LT LTEP16717672.6T patent/LT3280710T/lt unknown
- 2016-04-08 UA UAA201710897A patent/UA120777C2/uk unknown
-
2017
- 2017-09-24 IL IL254629A patent/IL254629B/en active IP Right Grant
- 2017-10-03 CO CONC2017/0010052A patent/CO2017010052A2/es unknown
- 2017-10-03 CL CL2017002491A patent/CL2017002491A1/es unknown
- 2017-10-04 ZA ZA2017/06671A patent/ZA201706671B/en unknown
-
2018
- 2018-08-06 HK HK18110069.5A patent/HK1250710A1/zh unknown
-
2019
- 2019-02-14 CL CL2019000397A patent/CL2019000397A1/es unknown
-
2020
- 2020-05-04 HR HRP20200707TT patent/HRP20200707T1/hr unknown
- 2020-05-25 CY CY20201100495T patent/CY1123105T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20171738A1 (es) | Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos | |
EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
CY1122272T1 (el) | ΕΝΩΣΕΙΣ 3-ΚΥΚΛΟΕΞΕΝΥΛ ΚΑΙ ΚΥΚΛΟΕΞΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΟΥ ΙΝΔΟΛΙΟΥ ΚΑΙ ΙΝΔΑΖΟΛΙΟΥ ΩΣ RORgammaT ΑΝΑΣΤΟΛΕΙΣ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
CR20200393A (es) | Picolinamidas como fungicidas | |
CO2019011543A2 (es) | Inhibidores de pd-1/pd-l1 | |
CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
EA201792536A1 (ru) | Триазоловые агонисты рецептора apj | |
CL2017000521A1 (es) | Inhibidores de desmetilasa-1 específica a lisina | |
ECSP18012103A (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
EA201991197A1 (ru) | БЕНЗИМИДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
SV2018005723A (es) | Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos | |
EA201691913A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
TR201906366T4 (tr) | Polisiklik-karbamoilpiridon bileşiklerinin sentezi. | |
EA201891768A1 (ru) | Кристаллическая форма a агониста tlr7, ее способ получения и использование | |
EA201692525A1 (ru) | Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов | |
CO2018004473A2 (es) | Compuestos agonistas de ppar y composiciones farmaceuticas | |
CL2017000484A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
EA201692289A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
CO2018004573A2 (es) | Derivados de fenilo como agonistas del receptor 2 de cannabinoides | |
CY1125355T1 (el) | Πεντακυκλικη ενωση |